Analyzing Analyst Recommendations: Obsidian Energy Ltd. (OBE), Heron Therapeutics, Inc. (HRTX)

Obsidian Energy Ltd. (NYSE:OBE) tinted gains of +1.12% (0 points) to US$0.33. The volume of 1.01 Million shares climbed down over an trading activity of 1.09 Million shares. EPS ratio determined by looking at last 12 month figures is -0.37. Over the same time span, the stock marked US$1.24 as its best level and the lowest price reached was US$0.33. The corporation has a market cap of US$170.84 Million.

Obsidian Energy Ltd. (NYSE:OBE)’s earnings per share has been growing at a -20.4 percent rate over the past 5 year when average revenue increase was noted as -31.2 percent. The return on equity ratio or ROE stands at -12.1 percent while most common profitability ratio return on investment (ROI) was -6.5 percent. The company’s institutional ownership is monitored at 32.1 percent. The company’s net profit margin has achieved the current level of -56.4 percent and possesses 62.8 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 6 think it is Hold. Recently, analysts have updated the overall rating to 2.75. 3 analysts recommended Overweight these shares while 2 recommended Underweight, according to FactSet data.

Heron Therapeutics, Inc. (NASDAQ:HRTX) is worth US$2.07 Billion and has recently risen 1.11% to US$27.22. The latest exchange of 0.47 Million shares is below its average trading activity of 893.13 Million shares. The day began at US$26.86 but the price moved to US$26.86 at one point during the trading and finally capitulating to a session high of US$27.27. The stock tapped a 52-week high of US$42.9 while the mean 12-month price target for the shares is US$51.83.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 5.2, and a price to sales ratio of 35.21. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown -12.8%. With an institutional ownership near 0%, it carries an earnings per share ratio of -2.92.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 5 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 6 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.55.